Skip to main content
. 2022 Dec 9;20(1):370–382. doi: 10.1021/acs.molpharmaceut.2c00668

Figure 3.

Figure 3

Plasma (A), intestine (B), liver (D), and kidney tissue (F) profiles of NPP-669, BCV, and CDV in mice, with the corresponding CDV levels in the intestine (C) and the liver (E) after equimolar oral (NPP-669, BCV) and IV (CDV) dosing (n = 4, mean ± SD).